112 Hikma PHarmaceuticals Plc annual report 2011 notes to the consolidated financialstatements Continued 4. segmental reporting for management purposes, the Group is currently organised into three operating divisions Branded, injectables and Generics.
these divisions are the basis on which the Group reports its segmental information.
the Group discloses underlying operating profit as the measure of segmental result as this is the measure used in the decision-making and resource allocation process of the chief operating decision maker, who is the Groups chief executive Officer.
information regarding the Groups operating segments is reported below.
the following is an analysis of the Groups revenue and results by reportable segment in 2011: branded injectables generics others group year ended 31 december 2011 $000 $000 $000 $000 $000 revenue 441,907 315,728 154,813 5,577 918,025 cost of sales 227,830 188,151 102,609 4,086 522,676 Gross profit 214,077 127,577 52,204 1,491 395,349 Adjusted segment result 105,143 54,938 17,124 2,369 174,836 exceptional items: integration related expenses 921 4,551 5,472 inventory related adjustments 1,770 1,770 intangible amortisation 5,763 3,186 39 10 8,998 segment result 98,459 45,431 17,085 2,379 158,596 Adjusted unallocated corporate expenses 29,012 exceptional items: acquisition related expenses 10,896 unallocated corporate expenses 39,908 Adjusted operating profit 145,824 operating profit 118,688 results from associated companies 1,164 finance income 468 finance expense 23,368 other expense net 732 profit before tax 93,892 tax 10,423 profit for the year 83,469 attributable to: non-controlling interest 3,362 equity holders of the parent 80,107 83,469 intangible amortisation comprises the amortisation on intangible assets other than software.
Others mainly comprises arab medical containers ltd, international Pharmaceutical research center ltd and the chemicals division of HikmaPharmaceuticals ltd Jordan.
unallocated corporate expenses are primarily made up of employee costs, office costs, professional fees, donations, travel expenses and acquisition related expenses.
financial statements 113 Hikma PHarmaceuticals Plc annual report 2011 4. segmental reporting Continued corporate branded injectables generics and others group segment assets and liabilities 2011 $000 $000 $000 $000 $000 additions to property, plant and equipment cost 44,869 11,926 12,925 975 70,695 acquisition of subsidaries property, plant and equipment netbookvalue 24,125 50,071 74,196 additions to intangible assets 5,054 2,520 1,106 287 8,967 intangible assets arising on acquisition 110,900 40,324 151,224 total property, plant and equipment and intangible assets netbookvalue 527,240 244,725 50,759 7,437 830,161 depreciation 18,205 10,521 6,250 684 35,660 amortisation including software 7,064 3,748 307 224 11,343 interests in associated companies 37,445 37,445 Balance sheet total assets 958,709 389,819 168,526 58,588 1,575,642 total liabilities 490,523 197,271 31,514 57,700 777,008 the following is an analysis of the Groups revenue and results by reportable segment in 2010: branded injectables generics others group year ended 31 december 2010 $000 $000 $000 $000 $000 revenue 394,166 157,439 174,491 4,840 730,936 cost of sales 190,733 86,437 92,710 3,712 373,592 gross profit 203,433 71,002 81,781 1,128 357,344 Adjusted segment result 96,230 26,224 51,258 2,889 170,823 exceptional items: gains on revaluation of previously held equity interests 7,176 7,176 intangible amortisation 4,732 2,500 169 7,401 segment result 98,674 23,724 51,089 2,889 170,598 Adjusted unallocated corporate expenses 27,798 exceptional items: acquisition related expenses 7,705 unallocated corporate expenses 35,503 Adjusted operating profit 143,025 operating profit 135,095 finance income 346 finance expense 13,856 other expense net 603 profit before tax 120,982 tax 21,455 profit for the year 99,527 attributable to: non-controlling interest 678 equity holders of the parent 98,849 99,527 intangible amortisation comprises the amortisation on intangible assets other than software.
114 Hikma PHarmaceuticals Plc annual report 2011 notes to the consolidated financialstatements Continued 4. segmental reporting Continued corporate branded injectables generics and others group segment assets and liabilities 2010 $000 $000 $000 $000 $000 additions to property, plant and equipment cost 32,747 7,428 6,798 2,125 49,098 acquisition of subsidiarys property, plant and equipment netbookvalue 24,437 24,437 additions to intangible assets 2,147 1,902 5 20 4,074 intangible assets arising on acquisition 28,066 28,066 total property, plant and equipment and intangible assets netbookvalue 397,301 146,818 32,682 9,782 586,583 depreciation 16,032 5,517 6,373 1,169 29,091 amortisation including software 6,044 2,848 365 85 9,342 Balance sheet total assets 755,936 184,039 150,015 25,830 1,115,820 total liabilities 240,438 77,217 26,967 20,898 365,520 the following table provides an analysis of the Groups sales by geographical market, irrespective of the origin of the goods services: 2011 2010 $000 $000 middle east and north africa 508,776 446,524 united states 317,334 204,389 europe and rest of the world 87,622 79,133 united kingdom 4,293 890 918,025 730,936 the top selling markets in 2011 were the usa, saudi arabia and algeria with total sales of usD 317.3 million 2010: usD 204.4 million, usD 121.4 million 2010: usD 118.5 million and usD 102.5 million 2010: usD 88.8 million, respectively.
included in revenues arising from the Branded and injectables segments are revenues of approximately usD 101.9 million 2010:usD99.4million which arose from sales to the Groups largest customer which is located in saudi arabia.
the following is an analysis of the total non-current assets excluding deferred tax and financial instruments and an analysis of total assets by the geographical area in which the assets are located: total non-current assets excluding deferred tax and financial instruments as at 31 december total assets as at 31 december 2011 2010 2011 2010 $000 $000 $000 $000 middle east and north africa 567,935 417,076 1,019,288 774,402 europe 141,481 146,844 197,128 185,945 united states 131,589 33,589 349,705 150,018 united kingdom 800 431 9,521 5,455 841,805 597,940 1,575,642 1,115,820
